Press releases and financial reports
In the CombiGenes pressroom you will find press releases, newsletters, and the latest reports. High resolution images as well as logos are available for use in articles and in newsstands.
Copyright applies to all footage.
The board of directors of CombiGene AB (publ) ("CombiGene") has, on the basis of an authorization from the Annual General Meeting, resolved on a directed share issue of 1,561,365 shares to Lipigon Pharmaceuticals AB ("Lipigon") due to the license agreement previously...read more
CombiGene and CGT Catapult collaboration completes development of quality control analytical assays for clinical production of CombiGene’s AAV-based gene therapy for the treatment of epilepsy
The extensive and advanced work to develop the critical analytical assays needed for quality control in the manufacture of the AAV1 based gene therapy product CG01 has now been completed in a collaboration between CombiGene and Cell and Gene Therapy Catapult (CGT...read more
After having carried out a successful pilot production of CG01 in July at the Spanish gene therapy manufacturer Viralgen, CombiGene AB (publ) and Viralgen have today signed an agreement for the production of CG01. CombiGene’s reason for choosing Viralgen as a partner...read more
On August 31, 2020 the period for exercising warrants of series TO 3 for subscription of shares in CombiGene AB (publ) ("CombiGene" or "The Company") ended. In total, 29 450 679 warrants had been exercised for subscription of shares and each warrant entitled to...read more
Today, the exercise period for subscription of shares in CombiGene AB (publ) ("CombiGene") begins on the basis of warrants of series TO3. One warrant of series TO3 entitles to subscription for one new share in CombiGene from and including 17 August 2020 up to and...read more
Find it easy
"This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version shall prevail. For a complete list of regulatory-related press releases, please refer to the Swedish website"
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 firstname.lastname@example.org.